Please login to the form below
trial failures
This page shows the latest trial failures news and features for those working in and with pharma, biotech and healthcare.
Merck gets first approval for MET inhibitor tepotinib in Japan
combination. MET is known as a resistance mechanism for EGFR-positive NSCLC, and Merck also has a trial on the go of tepotinib plus Tagrisso in this setting. ... ArQule and Kyowa Hakko abandoned their MET inhibitor tivantinib in 2017 after a string of
Latest news
-
Northsea Therapeutics raises $40m to develop fish oil NASH drug
Looking for mid-stage trial success in field littered with failures. Following in Amarin’s footsteps, Dutch biotech Northsea Therapeutics has successfully raised $40m (36m) for the development of a fish ... French pharma Genfit also has a candidate
-
Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancer
The data from the phase 3 JAVELIN Bladder 100 trial has confirmed that Bavencio statistically improves survival in its approved patient population. ... The extension into the earlier indication in bladder cancer is vital for Bavencio, which has been
-
New efficacy data boosts Aimovig’s migraine market lead
Data from the active treatment phase of STRIVE looked at efficacy and safety of Aimovig (70 and 140 mg) in episodic migraine patients with prior preventive treatment failures. ... Trial data shows that 55% of patients on Aimovig 140 mg experienced at
-
Merck bulks up in cancer with $2.2bn Peloton buy
The biotech’s first phase 2 trial recruited patients with VHL mutations and is testing PT2977 as a monotherapy, while a second all-comer metastatic RCC trial is pairing the drug ... which has recently seen some late-stage trial failures involving
-
Realm toppled by second mid-stage trial flop
PR022 did not show the desired effect in this trial,” said Alex Martin, the biotech’s CEO. ... considerably after the twin trial failures.
More from news
Approximately 5 fully matching, plus 30 partially matching documents found.
Latest Intelligence
-
Interview: AstraZeneca's Susan Galbraith
major trial failures meaning the company was looking unlikely to fill the void created by patent expiries of key drugs.
-
An eye towards the biobetter in South Korea
Smaller entities such as Isu Abxis are listed companies whose stock prices and financial stability are especially vulnerable to trial failures. ... Some companies already have their biobetter pipelines in clinical trial stage.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
AstraZeneca hires Roche’s Pascal Soriot as CEO
a series of clinical trial failures leading to the departure of AZ's previous CEO Brennan in April, 2012.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Alzheimer’s disease: reviewing the immediate treatment horizon
However, the learnings from these ‘failures’ have paved the way for the robust pipeline of treatments that could potentially be coming to market in the next five years. ... A recent article by BLH Consultant David Cooney explored the bleak
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- FDA approves Roche’s Actemra COVID-19 trial
- 3 ways to increase patient retention rates in clinical trials
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
PMHub
Dice Medical Communications
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...
Latest intelligence
- 3 ways to increase patient retention rates in clinical trials
- Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
Quick links
Infographics
